<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505931</url>
  </required_header>
  <id_info>
    <org_study_id>1-2015-0095</org_study_id>
    <nct_id>NCT03505931</nct_id>
  </id_info>
  <brief_title>Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)</brief_title>
  <official_title>Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Prospective, multi-center single-arm observational study&#xD;
&#xD;
        -  A total of 100 subjects with femoropopliteal artery disease who meet all inclusion and&#xD;
           exclusion criteria will be included.&#xD;
&#xD;
        -  Patients will be followed clinically for 12 months after the procedure.&#xD;
&#xD;
        -  An imaging study (duplex ultrasound, CT or catheter-based angiography) follow-up&#xD;
           according to participating hospital's protocol will be performed at 12 months.&#xD;
&#xD;
        -  Ankle-brachial index, symptom status and presence of stent fracture will be evaluated at&#xD;
           12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment (day 0):&#xD;
&#xD;
      1) Written consent&#xD;
&#xD;
      Post PTA (Day 1 ~3):&#xD;
&#xD;
        1. Symptom: Rutherford class&#xD;
&#xD;
        2. Adverse event&#xD;
&#xD;
        3. Ankle-brachial index&#xD;
&#xD;
        4. Laboratory test: - eGFR, Cr, ALT, AST&#xD;
&#xD;
             -  Hb, WBC, platelet&#xD;
&#xD;
        5. Concomitant medication&#xD;
&#xD;
      Regular Follow-up Visits&#xD;
&#xD;
      Visit 1 (post-PTA 30±14 days):&#xD;
&#xD;
        1. Symptom: Rutherford class&#xD;
&#xD;
        2. Physical examination&#xD;
&#xD;
        3. Concomitant medication&#xD;
&#xD;
        4. Adverse event&#xD;
&#xD;
        5. Laboratory test:&#xD;
&#xD;
             -  AC glucose, eGFR, Cr, ALT, AST&#xD;
&#xD;
             -  Hb, WBC, platelet&#xD;
&#xD;
             -  Lipid level (total cholesterol, LDL-C, triglyceride, HDL-C)&#xD;
&#xD;
             -  HbA1c in case of DM&#xD;
&#xD;
             -  hsCRP&#xD;
&#xD;
      Visit 2 (post-PTA 6 months ± 30 days):&#xD;
&#xD;
        1. Symptoms: Rutherford class&#xD;
&#xD;
        2. Physical examination&#xD;
&#xD;
        3. Ankle-brachial index&#xD;
&#xD;
        4. Concomitant medication&#xD;
&#xD;
        5. Adverse event&#xD;
&#xD;
      Visit 3 (post-PTA 12 months ± 30 days): (Mandatory)&#xD;
&#xD;
        1. Symptoms: Rutherford class&#xD;
&#xD;
        2. Physical examination&#xD;
&#xD;
        3. Ankle-brachial index&#xD;
&#xD;
        4. Duplex ultrasound, CT, or catheter angiography&#xD;
&#xD;
        5. Concomitant medication&#xD;
&#xD;
        6. Adverse event 7) Biplane radiograph of femur for evaluation of stent fracture 8)&#xD;
           Laboratory test: - AC glucose, eGFR, Cr, ALT, AST&#xD;
&#xD;
             -  Hb, WBC, platelet&#xD;
&#xD;
             -  Lipid level (total cholesterol, LDL-C,triglyceride, HDL-C)&#xD;
&#xD;
             -  HbA1c in case of DM&#xD;
&#xD;
             -  hsCRP&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Primary patency</measure>
    <time_frame>at 12 months</time_frame>
    <description>Absence of stenosis &gt;50% by an follow-up imaging study (duplex ultrasound, CT or catheter-based angiography) at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial index</measure>
    <time_frame>at 12 months</time_frame>
    <description>Ankle-brachial index defined as the ratio of the blood pressure at the ankle to the blood pressure in the upper arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ruthford category</measure>
    <time_frame>at 12 months</time_frame>
    <description>Rutherford category - symptom status by Rutherford category</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>at 12 months</time_frame>
    <description>Target lesion revascularization - accumulative rate of repeat interventions or surgery for the treatment of symptomatic restenosis (&gt;50% stenosis) in the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent fracture rate</measure>
    <time_frame>at 12 months</time_frame>
    <description>stent fracture rate - incidence of stent fracture by radiographs or fluoroscopy in 2 different projections</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Symptomatic Peripheral Artery Disease With Femoropopliteal Lesions</condition>
  <condition>Moderate or Severe Claudication (Rutherford Category 2 or 3)</condition>
  <condition>Critical Limb Ischemia (Rutherford Category 4 or 5)</condition>
  <arm_group>
    <arm_group_label>Eluvia</arm_group_label>
    <description>Patients treated with Eluvia stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of Eluvia stent</intervention_name>
    <description>Implantation of Eluvia stent</description>
    <arm_group_label>Eluvia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic peripheral artery disease with femoropopliteal lesions:&#xD;
&#xD;
          -  Moderate or severe claudication (Rutherford category 2 or 3)&#xD;
&#xD;
          -  Critical limb ischemia (Rutherford category 4 or 5) Age: ≥19 years, but not older than&#xD;
             85 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19 years of older&#xD;
&#xD;
          -  Symptomatic peripheral artery disease: Moderate or severe claudication (Rutherford&#xD;
             category 2 or 3) and Critical limb ischemia (Rutherford category 4-5)&#xD;
&#xD;
          -  Femoropopliteal artery lesions with stenosis &gt; 50%&#xD;
&#xD;
          -  ABI &lt; 0.9 before treatment&#xD;
&#xD;
          -  Patents treated with ELUVIA stent for femoropopliteal artery disease&#xD;
&#xD;
          -  Patients with signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute critical limb ischemia&#xD;
&#xD;
          -  Severe critical limb ischemia (Rutherford category 6)&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to any of the following medications:&#xD;
             heparin, aspirin, clopidogrel, cilostazol, or contrast agents&#xD;
&#xD;
          -  In-stent restenosis lesions (Restenosis lesions without previously implanted stents&#xD;
             are eligible to the enrollment)&#xD;
&#xD;
          -  Bypass graft lesions&#xD;
&#xD;
          -  Age &gt; 85 years&#xD;
&#xD;
          -  Severe hepatic dysfunction (&gt; 3 times normal reference values)&#xD;
&#xD;
          -  Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding&#xD;
             diathesis&#xD;
&#xD;
          -  LVEF &lt; 40% or clinically overt congestive heart failure&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  Life expectancy &lt;1 year due to comorbidity&#xD;
&#xD;
          -  Untreated proximal inflow disease of the ipsilateral iliac arteries (more than 50%&#xD;
             stenosis or occlusion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Young-Guk Ko, MD</last_name>
      <phone>082-02-2228-8460</phone>
      <email>ygko@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral artery disease</keyword>
  <keyword>femoropopliteal</keyword>
  <keyword>drug-eluting stent</keyword>
  <keyword>restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

